For instance, VX-809 (lumacaftor) and the newest VX-661 (tezacaftor) have been approved by FDA as pharmacological chaperones for the treatment of cystic fibrosis, acting on the F508del mutation of CFTR associated with protein misfolding (Southern et al., 2020). Here, CFTR is linked to cystic fibrosis.